U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H24FN3O4
Molecular Weight 401.4314
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOXIFLOXACIN

SMILES

[H][C@]12CN(C[C@@]1([H])NCCC2)C3=C(OC)C4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O

InChI

InChIKey=FABPRXSRWADJSP-MEDUHNTESA-N
InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16337789 | https://www.ncbi.nlm.nih.gov/pubmed/20516287 | https://www.ncbi.nlm.nih.gov/pubmed/25801151 | https://www.ncbi.nlm.nih.gov/pubmed/11600361

Moxifloxacin is a synthetic antibacterial agent developed by Bayer AG (initially called BAY 12-8039) for oral and intravenous administration. Moxifloxacin, a fluoroquinolone, is available as the monohydrochloride salt of 1-cyclopropyl-7-[(S,S)-2,8diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3 quinoline carboxylic acid. Moxifloxacin is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avalon for oral treatment. In most countries, the drug is also available in the parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye). Its antibacterial spectrum includes enteric Gram-(−) rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-positive bacteria and anaerobes.

CNS Activity

Curator's Comment: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s061s062,021277s057s058lbl.pdf

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
800.0 nM [IC50]
9200.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
AVELOX

Approved Use

INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

9.4469757E11
Curative
AVELOX

Approved Use

INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

9.4469757E11
Curative
AVELOX

Approved Use

INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

9.4469757E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.1 mg/L
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.2 mg/L
400 mg 1 times / day multiple, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3.9 mg/L
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.5 mg/L
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
443.07 ng/ml
1 drop 4 times / day multiple, ocular
dose: 1 drop
route of administration: ocular
experiment type: multiple
co-administered:
MOXIFLOXACIN aqueous humor
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
36.1 mg × h/L
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
38 mg × h/L
400 mg 1 times / day multiple, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
39.3 mg × h/L
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
48 mg × h/L
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.55 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
14.8 h
400 mg 1 times / day multiple, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
11.8 h
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12.7 h
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
60%
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
60%
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day multiple, oral
Higher than recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: p.5
healthy, 30±7
n = 7
Health Status: healthy
Age Group: 30±7
Sex: M
Population Size: 7
Sources: Page: p.5
800 mg single, oral
Highest studied dose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources: Page: p.2062
healthy, 33.6
n = 8
Health Status: healthy
Age Group: 33.6
Sex: M
Population Size: 8
Sources: Page: p.2062
400 mg 1 times / day multiple, intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash
Sources: Page: p.8.9
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Disc. AE: Nausea, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Nausea (>0.3)
Diarrhea (>0.3)
Dizziness (>0.3)
Vomiting (>0.3)
Sources: Page: p.8.9
800 mg 1 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.7
unhealthy, 57.8
n = 5
Health Status: unhealthy
Condition: Chronic bronchitis
Age Group: 57.8
Sex: M+F
Population Size: 5
Sources: Page: p.7
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Co-administed with::
Linezolid, IV(600 mg q12h)
Sources: Page: p.1863
unhealthy, 59.6
n = 273
Health Status: unhealthy
Condition: Community-acquired bacterial pneumonia
Age Group: 59.6
Sex: M+F
Population Size: 273
Sources: Page: p.1863
Disc. AE: Erythema, QT interval prolonged...
AEs leading to
discontinuation/dose reduction:
Erythema (0.37%)
QT interval prolonged (1%)
Angioedema (serious, 0.37%)
Sources: Page: p.1863
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Disc. AE: Tendinitis, Tendon rupture...
AEs leading to
discontinuation/dose reduction:
Tendinitis
Tendon rupture
Peripheral neuropathy
Central nervous system disorder NOS
Myasthenia gravis
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Rash Disc. AE
400 mg 1 times / day multiple, intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Diarrhea >0.3
Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Dizziness >0.3
Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Nausea >0.3
Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Vomiting >0.3
Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Erythema 0.37%
Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Co-administed with::
Linezolid, IV(600 mg q12h)
Sources: Page: p.1863
unhealthy, 59.6
n = 273
Health Status: unhealthy
Condition: Community-acquired bacterial pneumonia
Age Group: 59.6
Sex: M+F
Population Size: 273
Sources: Page: p.1863
QT interval prolonged 1%
Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Co-administed with::
Linezolid, IV(600 mg q12h)
Sources: Page: p.1863
unhealthy, 59.6
n = 273
Health Status: unhealthy
Condition: Community-acquired bacterial pneumonia
Age Group: 59.6
Sex: M+F
Population Size: 273
Sources: Page: p.1863
Angioedema serious, 0.37%
Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Co-administed with::
Linezolid, IV(600 mg q12h)
Sources: Page: p.1863
unhealthy, 59.6
n = 273
Health Status: unhealthy
Condition: Community-acquired bacterial pneumonia
Age Group: 59.6
Sex: M+F
Population Size: 273
Sources: Page: p.1863
Central nervous system disorder NOS Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Myasthenia gravis Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Peripheral neuropathy Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Tendinitis Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Tendon rupture Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
PubMed

PubMed

TitleDatePubMed
Streptococcus pneumoniae as an agent of nosocomial infection: treatment in the era of penicillin-resistant strains.
2001
Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint.
2001
Comparison of side effects of levofloxacin versus other fluoroquinolones.
2001
Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers.
2001
Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline.
2001
Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans.
2001
Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.
2001
Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
2001
Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.
2001
Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers.
2001
Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers.
2001
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
2001 Apr
Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales.
2001 Apr
Reassuring safety profile of moxifloxacin.
2001 Apr 1
Determination of moxifloxacin in growth media by high-performance liquid chromatography.
2001 Apr 15
A whole blood bactericidal assay for tuberculosis.
2001 Apr 15
Treatment of Staphylococcus aureus endocarditis using moxifloxacin.
2001 Aug
A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae.
2001 Aug 15
Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features.
2001 Feb
Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin.
2001 Feb
[One year moxifloxacin. Still effective in the respiratory tract].
2001 Feb 15
Bactericidal activity of moxifloxacin against pneumococci.
2001 Jan
In vitro activity of moxifloxacin against Stenotrophomonas maltophilia blood isolates from patients with hematologic malignancies.
2001 Jan
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
2001 Jul
A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis.
2001 Jul-Aug
Microbial drug resistance and the roles of the new antibiotics.
2001 Jun
A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model.
2001 Jun
Conventional dogma applied to quinolones? Time for a change.
2001 Jun
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
2001 Jun
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
2001 Jun
Bactericidal activity of moxifloxacin against Staphylococcus aureus.
2001 Mar
In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
2001 Mar
What do the new antimicrobials offer? Weighing the advantages and disadvantages compared with traditional agents.
2001 Mar
Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography.
2001 Mar
Moxifloxacin: clinical efficacy and safety.
2001 Mar 1
Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
2001 Mar 15
Evaluation of the clinical microbiology profile of moxifloxacin.
2001 Mar 15
Profile of moxifloxacin drug interactions.
2001 Mar 15
Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
2001 Mar 15
Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.
2001 Mar 15
Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.
2001 Mar 15
Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118.
2001 Mar 15
Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients.
2001 Mar-Apr
Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin.
2001 Mar-Apr
Chronic obstructive pulmonary disease.
2001 Mar-Apr
Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses.
2001 Nov
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
2001 Oct
Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes.
2001 Oct
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
2001 Sep
Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
2001 Sep 15
Patents

Sample Use Guides

The dose of AVELOX is 400 mg (orally or as an intravenous infusion) once every 24 hours. The duration of therapy depends on the type of infection (5--21 days).
Route of Administration: Oral
In Vitro Use Guide
Phagocytosed bacteria were divided into four aliquots with different concentrations of the drug (0, 0.1, 1 and 10 MIC). At baseline and after 1, 2 and 4 h incubation, the number of viable bacteria was determined by a subculture technique. Moxifloxacin was active against all tested staphylococci with MICs of 0.063–2 mg/L.
Name Type Language
MOXIFLOXACIN
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
moxifloxacin [INN]
Common Name English
AVELOX IV
Brand Name English
1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-((4AS,7AS)-OCTAHYDRO-6H-PYRROLO(3,4-B)PYRIDIN-6-YL)-4-OXO-3-QUINOLINECARBOXYLIC ACID
Common Name English
Moxifloxacin [WHO-DD]
Common Name English
MOXIFLOXACIN [VANDF]
Common Name English
ZIMOXIN
Brand Name English
MOXIFLOXACIN [MI]
Common Name English
Classification Tree Code System Code
WHO-ATC S01AX22
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
WHO-ATC J01MA14
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
NCI_THESAURUS C795
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
NDF-RT N0000175937
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
WHO-VATC QS01AE07
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
WHO-VATC QJ01MA14
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
LIVERTOX NBK548166
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
WHO-ATC S01AE07
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
NDF-RT N0000007606
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
Code System Code Type Description
INN
7659
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
HSDB
8026
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
NCI_THESAURUS
C62052
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
WIKIPEDIA
MOXIFLOXACIN
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
CHEBI
63611
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
DAILYMED
U188XYD42P
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
LACTMED
Moxifloxacin
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
PUBCHEM
152946
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
CAS
151096-09-2
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
EVMPD
SUB09086MIG
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
ChEMBL
CHEMBL32
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
MERCK INDEX
M7647
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY Merck Index
RXCUI
139462
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY RxNorm
FDA UNII
U188XYD42P
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
SMS_ID
100000080618
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
DRUG BANK
DB00218
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
CAS
354812-41-2
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
NON-SPECIFIC STEREOCHEMISTRY
MESH
C104727
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
DRUG CENTRAL
1854
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY
EPA CompTox
DTXSID3048491
Created by admin on Thu Jul 06 22:21:51 UTC 2023 , Edited by admin on Thu Jul 06 22:21:51 UTC 2023
PRIMARY